Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock

Talphera, Inc. (NASDAQ:TLPH) insider Badri Dasu purchased 35,000 shares of Talphera stock in a transaction on Thursday, February 12th. The stock was purchased at an average price of $0.81 per share, for a total transaction of $28,350.00. Following the completion of the transaction, the insider owned 76,230 shares of the company’s stock, valued at approximately $61,746.30. This represents a 84.89% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Talphera Price Performance

Shares of TLPH traded down $0.03 on Friday, hitting $0.78. The company’s stock had a trading volume of 51,448 shares, compared to its average volume of 163,382. The company has a market capitalization of $36.20 million, a PE ratio of -2.04 and a beta of 0.46. Talphera, Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $1.57. The company has a 50 day moving average price of $1.00 and a 200 day moving average price of $0.99.

Institutional Investors Weigh In On Talphera

A number of institutional investors and hedge funds have recently modified their holdings of TLPH. Cantor Fitzgerald L. P. acquired a new position in Talphera in the fourth quarter valued at approximately $658,000. Diadema Partners LP acquired a new stake in Talphera during the 4th quarter worth $156,000. Persistent Asset Partners Ltd bought a new stake in shares of Talphera during the 4th quarter valued at $42,000. Mariner LLC lifted its stake in shares of Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Talphera by 412.6% in the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after purchasing an additional 207,166 shares during the last quarter. 37.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TLPH has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research report on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.